QR код

B. longum CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice

ABSTRACTThe gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes mellitus (T2DM). In this study, we investigated the synergistic potential of combining the effects of Bifidobacterium longum NBM7–1 (CKD1) with anti-diabetic medicines, LobeglitazoneⓇ (LO), SitagliptinⓇ (...

Повний опис

Збережено в:
Автори: Won Jun Kim, Bum Ju Kil, Chaewon Lee, Tae Young Kim, Goeun Han, Yukyung Choi, Kyunghwan Kim, Chang Hun Shin, Seung-Young Park, Heebal Kim, Myunghoo Kim, Chul Sung Huh
Формат: Artigo
Мова:Inglês
Опубліковано: Taylor & Francis Group 2024-12-01
Серія:Gut Microbes
Предмети:
Bifidobacterium longum CKD1
anti-diabetic medicines
IL-22 signaling
insulin resistance
hepatic steatosis
Онлайн доступ:https://www.tandfonline.com/doi/10.1080/19490976.2024.2319889
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси